Your session is about to expire
← Back to Search
Monoclonal Antibodies
PRA052 for Healthy Volunteers
Phase 1
Waitlist Available
Research Sponsored by Prometheus Biosciences, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Male or female (of non-childbearing potential only) between minimum adult legal age (according to local laws for signing the informed consent document) and 60 years of age.
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 20 weeks
Awards & highlights
Study Summary
This trial tests a new drug for safety, side effects, how it's absorbed and how it works in healthy people.
Who is the study for?
This trial is for healthy adult men and women (of non-childbearing potential) up to 60 years old. Participants must be in good health based on medical history, physical exams, chest x-rays, vital signs, ECGs, and lab tests. They should agree to use reliable contraception during the study.Check my eligibility
What is being tested?
The study is testing PRA052 against a placebo in healthy volunteers. It's designed to see how safe it is and how the body reacts to different doses over time. The process involves randomly assigning participants to receive either PRA052 or a placebo without knowing which one they're getting.See study design
What are the potential side effects?
Since this trial aims to determine the safety of PRA052, specific side effects are not yet known but will be monitored throughout the study.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between the legal adult age and 60, and cannot become pregnant.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 20 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 20 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Therapeutic procedure
Secondary outcome measures
ADA
Cmax
F%
+2 moreTrial Design
4Treatment groups
Experimental Treatment
Placebo Group
Group I: SAD Cohorts 1-8 Experimental ArmExperimental Treatment1 Intervention
Subjects will receive a single intravenous or subcutaneous dose of PRA052 in a dose escalation format
Group II: MAD Cohorts 1-5 Experimental ArmExperimental Treatment1 Intervention
Subjects will receive three subcutaneous or intravenous doses of PRA052, one dose every 2 weeks, in a dose escalation format
Group III: MAD Cohorts 1-5 Placebo ArmPlacebo Group1 Intervention
Subjects will receive three subcutaneous or intravenous doses of placebo, one dose every 2 weeks
Group IV: SAD Cohorts 1-8 Placebo ArmPlacebo Group1 Intervention
Subjects will receive a single intravenous or subcutaneous dose of placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PRA052
2022
Completed Phase 1
~100
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Prometheus Biosciences, Inc.Lead Sponsor
5 Previous Clinical Trials
503 Total Patients Enrolled
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Lead Sponsor
5 Previous Clinical Trials
503 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I will use contraception during and up to 12 weeks after my treatment.I have or had tuberculosis that was not fully treated.You have a history of alcohol or drug abuse in the last two years.I do not have any major health issues that could affect my participation in the study.You have had a severe allergic reaction to any medication before, according to the study doctor.I am between the legal adult age and 60, and cannot become pregnant.My recent tests and check-ups show I am in good health.
Research Study Groups:
This trial has the following groups:- Group 1: SAD Cohorts 1-8 Experimental Arm
- Group 2: MAD Cohorts 1-5 Placebo Arm
- Group 3: MAD Cohorts 1-5 Experimental Arm
- Group 4: SAD Cohorts 1-8 Placebo Arm
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Healthy Subjects Patient Testimony for trial: Trial Name: NCT05603182 — Phase 1
Share this study with friends
Copy Link
Messenger